{"disease":{"id":"alopecia","name":"Alopecia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":12},"drugs":{"marketed":[{"drug_id":"deuruxolitinib","indication_name":"severe alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leqselvi","generic_name":"DEURUXOLITINIB","company_name":"Sun Pharm Inds Inc","drug_phase":"marketed","molecular_target":"JAK1, JAK2, TYK2","drug_class":"","quality_score":77,"revenue":"2600","mechanism":"Deuruxolitinib inhibits JAK1, JAK2, and TYK2, modulating cytokine and growth factor signaling involved in hematopoiesis and immune function."},{"drug_id":"deuruxolitinib","indication_name":"Severe alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leqselvi","generic_name":"DEURUXOLITINIB","company_name":"Sun Pharm Inds Inc","drug_phase":"marketed","molecular_target":"JAK1, JAK2, TYK2","drug_class":"","quality_score":77,"revenue":"2600","mechanism":"Deuruxolitinib inhibits JAK1, JAK2, and TYK2, modulating cytokine and growth factor signaling involved in hematopoiesis and immune function."},{"drug_id":"baricitinib","indication_name":"Alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Olumiant","generic_name":"baricitinib","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase JAK2","drug_class":"Janus Kinase Inhibitor [EPC]","quality_score":50,"revenue":"1200","mechanism":""},{"drug_id":"ritlecitinib","indication_name":"Alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Litfulo","generic_name":"ritlecitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ITK/TSK","drug_class":"","quality_score":52,"revenue":null,"mechanism":"Litfulo works by blocking the activity of a specific enzyme called tyrosine-protein kinase ITK/TSK."},{"drug_id":"olumiant","indication_name":"Alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olumiant","company_name":"NHS Greater Glasgow and Clyde","drug_phase":"marketed","molecular_target":"Casein kinase I isoform gamma-1, Citron Rho-interacting kinase, Mitogen-activated protein kinase kinase kinase 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"cepharanthine","indication_name":"Alopecia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cepharanthin","generic_name":"CEPHARANTHINE","company_name":"","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase catalytic subunit alpha-1","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone-hexacetonide","indication_name":"Alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aristospan","generic_name":"TRIAMCINOLONE HEXACETONIDE","company_name":"Ethypharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe alopecia areata in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06651600","indication_name":"Alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Litfulo","generic_name":"pf-06651600","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ITK/TSK","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Litfulo works by blocking the ITK/TSK enzyme, which helps to stop the immune system from attacking hair follicles."},{"drug_id":"pf-06651600","indication_name":"Severe alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Litfulo","generic_name":"pf-06651600","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ITK/TSK","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Litfulo works by blocking the ITK/TSK enzyme, which helps to stop the immune system from attacking hair follicles."},{"drug_id":"minoxidil","indication_name":"Alopecia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rogaine","generic_name":"minoxidil","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"ATP-sensitive inward rectifier potassium channel 1, Sulfonylurea receptor 2, Kir6.2","drug_class":"Vasodilator (potassium channel opener), Hair growth stimulant","quality_score":null,"revenue":null,"mechanism":"Potassium channel opener that stimulates hair follicles (topical) or causes arteriolar vasodilation (oral) for hair loss and severe hypertension."},{"drug_id":"litfulo","indication_name":"Alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Litfulo","generic_name":"Ritlecitinib Tosylate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family","drug_class":"Kinase inhibitor","quality_score":63,"revenue":null,"mechanism":"Ritlecitinib irreversibly inhibits JAK3 and TEC kinase family by blocking ATP binding site."},{"drug_id":"ritlecitinib-20-mg","indication_name":"Moderate to severe alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ritlecitinib 20 mg","generic_name":"ritlecitinib-20-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK3/STAT3 pathway","drug_class":"small molecule inhibitor","quality_score":22,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":15,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05727306","title":"Healthcare Disparities in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":4052231,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT06283316","title":"Systemic Treatments for Alopecia Areata Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT05084417","title":"A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"OM1, Inc.","has_results":false},{"nct_id":"NCT05745389","title":"CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"CorEvitas","has_results":false},{"nct_id":"NCT07152119","title":"A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT02494297","title":"DUS on the Prescribing Indications for CPA/EE in 5 European Countries","phase":"","overall_status":"COMPLETED","enrollment_count":1597,"lead_sponsor_name":"Center for Epidemiology and Health Research, Germany","has_results":true},{"nct_id":"NCT06562270","title":"CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"CorEvitas","has_results":false},{"nct_id":"NCT06648850","title":"Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1120,"lead_sponsor_name":"Applied Biology, Inc.","has_results":false},{"nct_id":"NCT04006457","title":"Long-Term PF-06651600 for the Treatment of Alopecia Areata","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1057,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05928169","title":"Determinants of Chronic Inflammatory Skin Disease Trajectories","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University Hospital Schleswig-Holstein","has_results":false},{"nct_id":"NCT01231607","title":"Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":917,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06531109","title":"Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib","phase":"","overall_status":"RECRUITING","enrollment_count":850,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03570749","title":"A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":784,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT05914805","title":"A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":762,"lead_sponsor_name":"Cassiopea SpA","has_results":false},{"nct_id":"NCT06622824","title":"To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":756,"lead_sponsor_name":"Suzhou Kintor Pharmaceutical Inc,","has_results":false},{"nct_id":"NCT06126965","title":"Phase III Study of KX-826 With Adult Male Patients With AGA","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":740,"lead_sponsor_name":"Suzhou Kintor Pharmaceutical Inc,","has_results":false},{"nct_id":"NCT03732807","title":"PF-06651600 for the Treatment of Alopecia Areata","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":718,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01004809","title":"AVODART® Alopecia Post-marketing Surveillance (PMS)","phase":"","overall_status":"COMPLETED","enrollment_count":712,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT04518995","title":"Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":706,"lead_sponsor_name":"Concert Pharmaceuticals","has_results":true},{"nct_id":"NCT03742518","title":"A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":675,"lead_sponsor_name":"Biosplice Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03899259","title":"A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":606,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT04925180","title":"A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06873945","title":"A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":550,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04797650","title":"Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":517,"lead_sponsor_name":"Concert Pharmaceuticals","has_results":true},{"nct_id":"NCT06501924","title":"Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":516,"lead_sponsor_name":"Applied Biology, Inc.","has_results":false},{"nct_id":"NCT06279221","title":"Litfulo Capsules Special Investigation","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":487,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03004469","title":"Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":458,"lead_sponsor_name":"Polichem S.A.","has_results":true},{"nct_id":"NCT03976622","title":"Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata","phase":"","overall_status":"UNKNOWN","enrollment_count":450,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT04014413","title":"Safety and Efficacy of Fecal Microbiota Transplantation","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT05051761","title":"Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":425,"lead_sponsor_name":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","has_results":false},{"nct_id":"NCT05041803","title":"European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"Sun Pharmaceutical Industries, Inc.","has_results":true},{"nct_id":"NCT06801821","title":"Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT07294313","title":"Harnessing Artificial Intelligence for Diagnosing Androgenetic Alopecia: A Training and Validation Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT00179348","title":"Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":399,"lead_sponsor_name":"Albert Einstein College of Medicine","has_results":false},{"nct_id":"NCT06802705","title":"Psychosocial Stress on QOL in Saudi Arabian Patients With Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":398,"lead_sponsor_name":"University of Jeddah","has_results":false},{"nct_id":"NCT07529977","title":"Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":372,"lead_sponsor_name":"Eurofarma Laboratorios S.A.","has_results":false},{"nct_id":"NCT04721548","title":"Treatment of Androgenetic Alopecia in Men for 24 Weeks","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":336,"lead_sponsor_name":"Eurofarma Laboratorios S.A.","has_results":false},{"nct_id":"NCT07516561","title":"Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":336,"lead_sponsor_name":"Apsen Farmaceutica S.A.","has_results":false},{"nct_id":"NCT05470413","title":"Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":330,"lead_sponsor_name":"Reistone Biopharma Company Limited","has_results":false},{"nct_id":"NCT04784533","title":"A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":317,"lead_sponsor_name":"Concert Pharmaceuticals","has_results":true},{"nct_id":"NCT06512766","title":"a Retrospective Study on the Systemic Treatment of LPP and FFA","phase":"","overall_status":"COMPLETED","enrollment_count":315,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT05255237","title":"Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":315,"lead_sponsor_name":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","has_results":false},{"nct_id":"NCT04898166","title":"Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Syeda Mahanum Ali","has_results":true},{"nct_id":"NCT07226531","title":"Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06324695","title":"Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin disEases","phase":"NA","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT07101471","title":"Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation","phase":"","overall_status":"COMPLETED","enrollment_count":296,"lead_sponsor_name":"NanoAlvand","has_results":false},{"nct_id":"NCT06916793","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":288,"lead_sponsor_name":"Chong Kun Dang Pharmaceutical","has_results":false},{"nct_id":"NCT04446429","title":"Anti-Androgen Treatment for COVID-19","phase":"NA","overall_status":"COMPLETED","enrollment_count":268,"lead_sponsor_name":"Applied Biology, Inc.","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}